Prescription drug prices dropped 1 percent in 2018 – the first time such a drop has occurred in the United States in 45 years – driven primarily by a greater reliance on generic drugs and much slower increases in branded drugs, according to a government study.

Mallinckrodt Plc received a subpoena from the U.S. Securities and Exchange Commission for documents related to the drugmaker’s lawsuit against the U.S. Department of Health and Human Services (HHS).

The U.S. Centers for Medicare and Medicaid Services finalized a decision to cover expensive cancer cell therapies sold by Gilead Sciences Inc. and Novartis AG.

HHS announced its new price transparency rules for direct-to-consumer TV ads. Now the industry has to sort out what to do about them.

Enrollments in healthcare plans for 2019 through the Federal Obamacare marketplace dropped marginally by 300,000 from 2018, according to U.S. government figures.

NEW YORK, March 22, 2019 /PRNewswire/ — A leading quality rating for the nation’s hospitals appears not to adequately account for the risks of undergoing certain procedures at certain hospitals, particularly joint replacement surgery, according to a new study by researchers at Hospital for Special Surgery (HSS) in New York City. The study, reported in the […]

U.S. health spending is expected to grow at an average rate of 5.5 percent yearly from 2018 over the next decade and will reach nearly $6 trillion by 2027 as more people become eligible for Medicare.

Evidenced by the move to measure and reimburse providers based on the quality, as opposed to the quantity, of care delivered, the healthcare industry is shifting from a fee-for-service to an outcomes or value-based model.

Healthcare spending growth in the United States slowed for the second year in a row in 2017, mainly due to slower spending growth for hospital care, physician and clinical services as well as retail prescription drugs, according to a report from the U.S. Centers for Medicare and Medicaid Services.

Two partners at the hedge fund Deerfield Management and two others were found guilty of charges stemming from what prosecutors have described as an insider trading scheme based on leaks from within a federal healthcare agency.